POS-108 A PHASE 1/2, MULTICENTER TRIAL TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IgA NEPHROPATHY

IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally, with up to 45% of IgAN patients at risk progressing ESKD. There are currently no approved treatments specifically for nephropathy. The initiating step in pathogenesis excess production galactose-deficient IgA1 (Gd-IgA1) resulting formation pathogenic immune complexes that cause kidney inflammation and damage. A Proliferation-Inducing Ligand (APRIL), a TNF-superfamily cytokine, elevated correlated higher levels Gd-IgA1 proteinuria, lower eGFR.